Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Share-based Compensation (2016 - 2025)

Vanda Pharmaceuticals' Share-based Compensation history spans 16 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 20.19% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $9.5 million, down 23.79%, while the annual FY2025 figure was $9.5 million, 23.79% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.3 million at Vanda Pharmaceuticals, up from $2.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.8 million in Q1 2022 and bottomed at $2.1 million in Q2 2025.
  • The 5-year median for Share-based Compensation is $3.4 million (2023), against an average of $3.4 million.
  • The largest annual shift saw Share-based Compensation increased 26.03% in 2021 before it dropped 29.58% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2021, then grew by 0.24% to $3.8 million in 2022, then decreased by 13.48% to $3.3 million in 2023, then dropped by 12.53% to $2.9 million in 2024, then dropped by 20.19% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Share-based Compensation are $2.3 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025).